Entera Bio Ltd. (ENTX)

USD 2.18

(-1.36%)

Market Cap (In USD)

80.29 Million

Revenue (In USD)

-

Net Income (In USD)

-8.88 Million

Avg. Volume

45.96 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.52-3.35
PE
-
EPS
-
Beta Value
1.59
ISIN
IL0011429839
CUSIP
M40527109
CIK
1638097
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Miranda J. Toledano M.B.A.
Employee Count
-
Website
https://www.enterabio.com
Ipo Date
2018-06-28
Details
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.